The recent decision by the FDA to restrict compounded versions of popular weight loss medications such as Ozempic and Zepbound has sparked panic among patients seeking affordable alternatives. With the production of cheaper alternatives expected to stop soon, many people are concerned about losing access to these vital medications. Telehealth companies have expressed dissatisfaction with the impending changes, fearing that it might limit options for their patients. As weight loss drug shortages are officially deemed over, compounded GLP-1 drugs face significant legal and regulatory challenges, forcing patients to scramble for access to remaining supplies. Amid increasing frustration from both patients and healthcare providers, the ongoing developments raise questions about the future affordability and availability of weight loss injections.